Last reviewed · How we verify
Weekly Paclitaxel and Carboplatin
Weekly Paclitaxel and Carboplatin is a Small molecule drug developed by Hospices Civils de Lyon. It is currently in Phase 2 development.
At a glance
| Generic name | Weekly Paclitaxel and Carboplatin |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer (PHASE2)
- Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery (PHASE2, PHASE3)
- Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer (PHASE3)
- A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Weekly Paclitaxel and Carboplatin CI brief — competitive landscape report
- Weekly Paclitaxel and Carboplatin updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI
Frequently asked questions about Weekly Paclitaxel and Carboplatin
What is Weekly Paclitaxel and Carboplatin?
Weekly Paclitaxel and Carboplatin is a Small molecule drug developed by Hospices Civils de Lyon.
Who makes Weekly Paclitaxel and Carboplatin?
Weekly Paclitaxel and Carboplatin is developed by Hospices Civils de Lyon (see full Hospices Civils de Lyon pipeline at /company/hospices-civils-de-lyon).
What development phase is Weekly Paclitaxel and Carboplatin in?
Weekly Paclitaxel and Carboplatin is in Phase 2.
Related
- Manufacturer: Hospices Civils de Lyon — full pipeline